about
Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Needle-free influenza vaccination.Dried influenza vaccines: over the counter vaccines.Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation.A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer.Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.Towards tailored vaccine delivery: needs, challenges and perspectives.Devices and formulations for pulmonary vaccination.Aspartate buffer and divalent metal ions affect oxytocin in aqueous solution and protect it from degradation.Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage.Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.Effect of drug-carrier interaction on the dissolution behavior of solid dispersion tablets.Feasibility of nonvolatile buffers in capillary electrophoresis-electrospray ionization-mass spectrometry of proteins.Development of a dry, stable and inhalable acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections.The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix.Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization.Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production.Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01.Self-exploding lipid-coated microgels.Inulin as filler-binder for tablets prepared by direct compactionSurface-active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug loadA new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrateEfficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in ratsFormulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalationPreparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administrationDevelopment of an Orodispersible Film Containing Stabilized Influenza VaccineOvalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice
P50
Q30386212-7711606F-D33A-4A98-B9A6-11443CDD9218Q30394326-3072C647-5B75-4076-9B7C-6AC2BA85BFDDQ30394651-096ABD5C-B81C-440D-B2B7-3EF7CF46B1ADQ30795362-A9DCF4C0-4C3D-4568-B5F8-D08932D803E1Q34901001-72751A84-8AFC-49F1-9B48-AB7334E6E59FQ34914845-B8DD6144-1BD6-4A6F-B931-417E278B8D38Q37896655-93DDA138-465A-421E-990E-C00BAA8DFB53Q37975885-AD3DB372-E79D-481C-B631-FECED0F8E628Q38115814-9AE324D3-D484-4653-99A8-A0580D29D92DQ38884223-7EB9CFCC-3375-4F3F-89D1-907BCCABAA55Q39770621-84C8FF08-D28B-4976-A1B1-D34169DDFFA3Q40107542-0EA3F4B6-9ECE-4875-B497-FCD46C4B82CBQ42374146-55FBDCD4-1235-4818-BACA-9FFE71895854Q42927549-A0294788-1D32-4519-90F8-AB6AF7B39355Q44733571-91021246-EB65-4C14-9669-A81570BE5B3AQ44884812-AA66CA00-35D4-49DB-9DEC-F47D3B3C5BC7Q45080289-EC9E5017-712E-4E57-BA9C-3892E11ED056Q45367139-01462F7B-6AA9-4DA5-B463-159D7EB84B8FQ45920457-49FC570A-37D1-41DF-BC3F-E60858751288Q46023040-06A74939-5834-4575-9E47-858652E474F6Q46883773-1BC3110F-BD5B-4F52-AB8A-338373F54349Q77526214-31D4F36A-659A-4C20-AE5B-A08FF69E9155Q83258662-DA7CF8A1-10BC-4CC8-9E1F-CCA0CD89A8ADQ83274133-2F5B04A9-4296-4B92-851D-F491CD0E9681Q83772488-1B63AFC3-BAC2-4A10-87A9-963F91B6AA51Q84120587-12F59F2E-6269-4477-8C99-BB41F2639F0AQ85023007-0205509B-8F68-41CA-99AB-5913186A0104Q90393531-1BD6D82F-1E98-4E41-B602-FFBB1AE57008Q91224067-52FE2EEF-8C7A-41A8-8F3A-F227BA574D8E
P50
description
researcher
@en
wetenschapper
@nl
name
Wouter L J Hinrichs
@en
Wouter L J Hinrichs
@nl
type
label
Wouter L J Hinrichs
@en
Wouter L J Hinrichs
@nl
prefLabel
Wouter L J Hinrichs
@en
Wouter L J Hinrichs
@nl
P106
P31
P496
0000-0002-1481-2769